Skip to main content Deutsch


Victoria Weissenböck
Victoria Weissenböck

Department of Biomedical Imaging and Image-guided Therapy (Division of Nuclear Medicine)
Position: Technical Staff


Autoradiography; Drug Evaluation, Preclinical; Positron-Emission Tomography; Radioactive Tracers

Research group(s)

Research interests

The tumour microenvironment (TME) is gaining tremendous traction in cancer targeting for imaging-based diagnostics, and therapy. Within the TME, the fibroblast growth factor(FAP) is a potential new target for the theragnostic concept and gallium-68 and lutetium-177 labelled ligands have been used. However,  there are a plethora of other diseases which can be targeted by FAP-ligands, especially fibrosis is of interest. Therefore, my master thesis deals with the preclinical evaluation of [68Ga]Ga DATA.SA.FAPi for imaging of fibrosis in three different mouse models: a myocardial infarction model induced by surgery, causing fibrogenesis; a model using pharmacological treatment with the antibiotics Bleomycin, showing the development of fibrosis as side effect; and genetic fibrosis mouse model.

Within the experimental nuclear medicine, I hold a position as technician. Part of my work is  radiolabelling of different peptides with Ga-68 and Lu-177 and small molecules with F-18, and C-11. Furthermore, I am involved in preclinical studies and responsible for ex vivo biodistribution, cell culturing, as well as autoradiography (AURA) and immunohistochemistry (IHC) staining.

Techniques, methods & infrastructure

  • Radiosynthesis
  • Binding-studies (cell culture)
  • Metabolism
  • Autoradiography
  • Immunhistochemistry
  • Small animal PET/CT
  • Biodistribution
  • MACS
  • FACS

Selected publications

  1. Klebermass, E.-M. et al. (2022) ‘Autoradiography on deparaffinized tissue sections – A feasibility study with 68Ga-labeled PET-tracers’, Applied Radiation and Isotopes, 189, p. 110425. Available at: